Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, TX 76798-7348, USA.
Bioorg Med Chem. 2009 Oct 1;17(19):6993-7001. doi: 10.1016/j.bmc.2009.08.011. Epub 2009 Aug 12.
Structural redesign of selected non-steroidal estrogen receptor binding compounds has previously been successful in the discovery of new inhibitors of tubulin assembly. Accordingly, tetra-substituted alkene analogues (21-30) were designed based in part on combinations of the structural and electronic components of tamoxifen and combretastatin A-4 (CA4). The McMurry coupling reaction was used as the key synthetic step in the preparation of these tri- and tetra-arylethylene analogues. The structural assignment of E, Z isomers was determined on the basis of 2D-NOESY experiments. The ability of these compounds to inhibit tubulin polymerization and cell growth in selected human cancer cell lines was evaluated. Although the compounds were found to be less potent than CA4, these analogues significantly advance the known structure-activity relationship associated with the colchicine binding site on beta-tubulin.
先前的研究表明,对选定的非甾体雌激素受体结合化合物进行结构重新设计,成功发现了新的微管蛋白组装抑制剂。因此,根据他莫昔芬和考布他汀 A-4(CA4)的结构和电子部分的组合,设计了四取代烯烃类似物(21-30)。麦克默里偶联反应被用作这些三芳基和四芳基乙烯类似物制备的关键合成步骤。根据 2D-NOESY 实验确定 E、Z 异构体的结构分配。评估了这些化合物在选定的人癌细胞系中抑制微管蛋白聚合和细胞生长的能力。虽然这些化合物的效力比 CA4 低,但这些类似物显著推进了与β-微管蛋白上的秋水仙素结合位点相关的已知结构-活性关系。